KUALA LUMPUR, July 7 (Bernama) -- Slingshot Biosciences Inc, the developer of synthetic cells, has announced extending its distribution channel through a new agreement with Chameleon Science.
The agreement entitles Chameleon Science the rights to distribute and resell Slingshot Bio’s products in Australia, New Zealand and Singapore, according to a statement.
Chameleon Science is an innovative new company specialising in the development and distribution of emerging technologies in Life Sciences.
Through Chameleon Science’s network of customers, Slingshot Bio will be able to build its presence in these markets with the well-established presence and expertise of Chameleon Science who has been selling into the flow cytometry industry for many years.
“Chameleon Science’s network will provide us with the market penetration needed to reach our full sales potential in key markets,” said Jeffrey Kim, CEO & Founder, Slingshot Biosciences Inc.
“Slingshot Biosciences has considered many distribution partners and we are confident that Chameleon Science’s extensive knowledge in the field, prominent presence and large customer base will help us leverage our position in the flow cytometry market.”
Meanwhile, Kathryn Friend, Director, Chameleon Science said: “Chameleon Science is excited to introduce Slingshot’s cellular controls to the region. This disruptive technology fills a large gap in the market for flow and spectral cytometry researchers.”
Slingshot Bio’s synthetic cellular controls provide consistent, precise, accurate control for research and clinical end-users that rely on flow cytometry by mimicking blood.
The ability to manufacture consistent controls for flow cytometry has been missing for decades and is now accessible with Slingshot Bio’s unique manufacturing platform.
For more information, visit www.slingshotbio.com.
-- BERNAMA
No comments:
Post a Comment